Genetics company 23andMe enters the telehealth market
23andMe will pay $400 million for drug-delivery service Lemonaid in a bid to make its personalized genetics approach part of patients’ primary care.
By Kristen V. Brown|October 26, 2021 at 10:47 AM
Thank you for sharing!
Your article was successfully shared with the contacts you provided.
(Bloomberg) –Consumer DNA testing giant 23andMe Holding Co. agreed to purchase telehealth upstart and drug-delivery service Lemonaid Health Inc. in a bid to make its personalized genetics approach part of patients’ primary care.
23andMe will pay $400 million for Lemonaid, with 25% of the purchase price in cash and the rest in stock, according to a statement Friday. The acquisition is expected to close by the end of the year.
Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.
Your access to unlimited BenefitsPRO.com content isn’t changing. Once you are an ALM digital member, you’ll receive:
Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
'Tis the season for changes to primary medical plans. Download this infographic and learn 4 actionable solutions to help save your clients from the gloom of a new primary plan reality before it's too late.